Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

• Published in: Brain sciences Vol. 10; no. 10; p. 758
• Main Authors: Florou, Despoina, Katsara, Maria, Feehan, Jack, Dardiotis, Efthimios, Apostolopoulos, Vasso
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 20.10.2020; MDPI AG
• Subjects: B-cell therapies; monoclonal antibodies; multiple sclerosis; Review; safety; B-cell therapies; multiple sclerosis; safety; monoclonal antibodies

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B cells play a crucial role in the pathogenesis of MS via antigen-driven autoanti...